Figures & data
Table 1 Patient demographics and baseline characteristics (intent-to-treat population)
Table 2 Treatment exposure
Figure 1 Kaplan–Meier analysis of progression-free survival in the East Asian population.
Abbreviations: R-CHOP, rituximab + cyclophosphamide, doxorubicin, vincristine, prednisone; VR-CAP, bortezomib, rituximab, cyclophosphamide, doxorubicin, prednisone.
Table 3 Response rates in VR-CAP versus R-CHOP arms by Independent Radiology Review Committee and investigator assessment
Figure 2 Kaplan–Meier analysis of (A) time to next antilymphoma therapy and (B) overall survival, in the East Asian population (intent-to-treat population).
Table 4 Most common adverse events (safety populationTable Footnotea)
Table 5 Adverse events of clinical interest: thrombocytopenia, neutropenia, and peripheral neuropathy (safety population)
Table S1 Institutional review boards (IRBs) and ethics committees (ECs)
Figure S1 Patient disposition (CONSORT diagram).
